Key Points
- Edwards VP Daniel Lippis sold 1,019 shares on Jan. 9 at an average price of $85.70 for about $87,328, and now directly owns 22,002 shares (a 4.43% reduction in his stake), according to an SEC filing.
- Recent quarter beat expectations: Edwards reported Q results of $0.67 EPS (vs. $0.59 expected) and $1.55B revenue (vs. $1.49B), with revenue up 14.7% year-over-year, and set FY2025 EPS guidance of $2.560–$2.620 (Q4 guidance $0.580–$0.640).
- The stock is trading in the mid-$80s (50-day ~$85, 200-day ~$80) with a market cap of ~$49.4B, and analysts hold an average rating of "Moderate Buy" with an average price target of $94.57.
Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) VP Daniel Lippis sold 1,019 shares of the company's stock in a transaction that occurred on Friday, January 9th. The stock was sold at an average price of $85.70, for a total value of $87,328.30. Following the sale, the vice president directly owned 22,002 shares in the company, valued at $1,885,571.40. This trade represents a 4.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Edwards Lifesciences Stock Up 0.7%
NYSE EW opened at $85.14 on Friday. The stock has a 50 day moving average price of $85.06 and a 200-day moving average price of $80.32. Edwards Lifesciences Corporation has a one year low of $65.94 and a one year high of $87.89. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00. The company has a market capitalization of $49.41 billion, a P/E ratio of 36.70, a P/E/G ratio of 3.44 and a beta of 0.95.
Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The company had revenue of $1.55 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter in the prior year, the firm earned $0.67 earnings per share. Edwards Lifesciences's revenue was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. As a group, equities analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.
Institutional Investors Weigh In On Edwards Lifesciences
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Level Four Advisory Services LLC lifted its stake in shares of Edwards Lifesciences by 3.7% during the 3rd quarter. Level Four Advisory Services LLC now owns 3,301 shares of the medical research company's stock worth $257,000 after purchasing an additional 119 shares during the last quarter. Colonial Trust Co SC boosted its holdings in shares of Edwards Lifesciences by 0.4% in the 3rd quarter. Colonial Trust Co SC now owns 32,196 shares of the medical research company's stock valued at $2,504,000 after buying an additional 120 shares in the last quarter. Parkside Financial Bank & Trust grew its position in shares of Edwards Lifesciences by 9.8% in the 2nd quarter. Parkside Financial Bank & Trust now owns 1,455 shares of the medical research company's stock worth $114,000 after buying an additional 130 shares during the last quarter. Prosperity Consulting Group LLC raised its stake in shares of Edwards Lifesciences by 3.2% during the 2nd quarter. Prosperity Consulting Group LLC now owns 4,304 shares of the medical research company's stock worth $337,000 after acquiring an additional 132 shares in the last quarter. Finally, Howard Capital Management Inc. lifted its position in Edwards Lifesciences by 3.3% during the third quarter. Howard Capital Management Inc. now owns 4,136 shares of the medical research company's stock valued at $322,000 after acquiring an additional 132 shares during the last quarter. Institutional investors own 79.46% of the company's stock.
Wall Street Analyst Weigh In
Several equities research analysts have weighed in on EW shares. Raymond James Financial raised Edwards Lifesciences from a "market perform" rating to an "outperform" rating and set a $96.00 price objective on the stock in a research note on Monday, November 3rd. Oppenheimer downgraded Edwards Lifesciences from an "outperform" rating to a "market perform" rating in a research report on Wednesday, October 8th. UBS Group set a $92.00 price target on Edwards Lifesciences in a research report on Friday, December 5th. Jefferies Financial Group set a $98.00 price objective on shares of Edwards Lifesciences and gave the company a "buy" rating in a research report on Wednesday, October 29th. Finally, BTIG Research restated a "buy" rating and issued a $103.00 target price (up previously from $100.00) on shares of Edwards Lifesciences in a report on Thursday, December 4th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $94.57.
View Our Latest Report on Edwards Lifesciences
About Edwards Lifesciences
(
Get Free Report)
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
